上海莱士血液制品股份有限公司2025年度利润分配预案公告及现金分红方案详解

上海莱士血液制品股份有限公司2025年度利润分配预案详细解读

一、报告核心要点

公司2025年度实现母公司净利润15.99亿元，经安永华明会计师事务所审计。
拟提取10%法定公积金（约1.60亿元），全年实际可供分配利润为58.03亿元。
2025年度利润分配预案：每10股派发现金股利0.33元（含税），预计分红总额2.17亿元，占扣除法定盈余公积后净利润的15.06%，占归属于上市公司股东的净利润的13.75%。
2025年前三季度已现金分红总额1.01亿元，全年现金分红总额预计为3.17亿元。
2025年公司通过回购专用证券账户回购股份6908万股，占总股本1.04%，成交金额4.75亿元。
2025年度现金分红（含前三季度分红和本年度分红）及回购股份总额7.92亿元，占2025年度归属于公司股东净利润的50.24%。
本次利润分配预案不涉及送红股或公积金转增股本，未触及深圳证券交易所风险警示情形。
若公司总股本因转股、回购、股权激励等变动，将按比例调整分配方案。
公司最近三年累计现金分红及回购总额17.34亿元，占最近三年平均净利润的比例超30%。
公司2025年完成收购南岳生物100%股权，进一步巩固全国血制品头部企业地位。
公司未持有交易性金融资产、衍生金融资产等非主业资产。
利润分配预案需经2025年度股东会审议通过后方可实施。

二、对投资者和股东的影响及需关注事项

分红政策明确，现金分红稳定：公司持续实施现金分红，2025年度分红占净利润比例合理，有助于提升投资者回报。
回购股份力度大：公司大规模回购股份，金额占净利润比例高，显示管理层对公司长期价值的信心，并有助于提升每股收益。
收购南岳生物：已完成100%股权收购，南岳生物成为控股子公司，将推动公司业务扩张和市场份额提升，未来盈利能力有望增强。
资金用途合理：留存利润将用于战略发展、业务拓展及日常经营，保障公司持续成长。
合规性强：分红方案符合中国证监会及深圳证券交易所相关法规，不触及风险警示情形。
股东会投票便利：公司将以现场及网络投票方式召开股东会，保障中小股东权益。
实施存在不确定性：分红预案需股东会审议通过，存在不确定性，投资者需关注后续公告。
财务稳健：公司未持有高风险金融资产，资金结构稳健。

三、潜在影响与市场关注

持续高比例现金分红及回购股份，反映公司盈利能力及对未来发展的信心，或对公司股价形成支撑。
南岳生物收购落地，行业竞争力加强，长期利好公司发展。
资金使用效率提升，有望进一步增强公司核心竞争力和盈利能力。
分红方案最终实施需股东会审议，建议投资者关注后续进展。

四、总结

上海莱士2025年度利润分配预案显示公司经营稳健，分红政策明确，回购股份力度大，收购南岳生物进一步强化行业地位，资金用途合理。整体利好投资者和股东中长期利益，值得重点关注。

免责声明

本文章仅为信息解读，不构成投资建议。利润分配预案尚未最终实施，投资者请关注公司后续公告并审慎决策。市场有风险，投资需谨慎。

Detailed Analysis of Shanghai RAAS Blood Products Co., Ltd. 2025 Profit Distribution Proposal

1. Key Points in the Report

The company achieved a net profit of RMB 1.599 billion in 2025 (parent company statements), audited by Ernst & Young Hua Ming.
10% legal reserve will be drawn (approx. RMB 160 million); total distributable profit for the year is RMB 5.803 billion.
2025 profit distribution proposal: RMB 0.33 cash dividend (tax included) per 10 shares, estimated total dividend RMB 217 million, accounting for 15.06% of net profit after legal reserve, and 13.75% of net profit attributable to shareholders.
Cash dividends for first three quarters of 2025 total RMB 100 million; annual cash dividend expected to reach RMB 317 million.
In 2025, the company repurchased 69.08 million shares via dedicated account, representing 1.04% of total share capital, with a transaction amount of RMB 474 million.
Total cash dividend (including quarterly and annual dividend) and share repurchase in 2025 is RMB 792 million, accounting for 50.24% of net profit attributable to shareholders.
No bonus shares or capital reserve to share capital conversion in this proposal, and no risk warning as per Shenzhen Stock Exchange rules.
If share capital changes due to convertible bonds, repurchase, incentive plans, or refinancing, distribution will be adjusted proportionally.
In the past three years, total cash dividend and share repurchase reached RMB 1.734 billion, over 30% of average net profit.
In 2025, completed 100% acquisition of Nanyue BioPharma, further solidifying leading market position.
No trading financial assets, derivative financial assets, or other non-core assets held.
Profit distribution proposal is subject to approval at the 2025 shareholders’ meeting.

2. Important Information for Shareholders

Stable Dividend Policy: Cash dividends continue, with a reasonable ratio, supporting investor returns.
Significant Share Repurchase: Large-scale repurchase reflects management’s confidence in company value; boosts earnings per share.
Acquisition of Nanyue BioPharma: 100% stake acquired, boosting business expansion and market share; future earnings potential enhanced.
Rational Use of Retained Profits: Funds will be used for strategic development, business expansion, daily operations, ensuring sustainable growth.
Compliance: Proposal meets CSRC and SZSE regulations; no risk warning triggered.
Shareholder Meeting Voting Convenience: Both on-site and online voting will be available, ensuring minority shareholder rights.
Implementation Uncertainty: Proposal needs shareholder approval; investors should follow subsequent announcements.
Financial Stability: No high-risk financial assets held, ensuring strong financial structure.

3. Potential Impacts and Market Focus

Consistent high cash dividends and share repurchases show strong profitability and management confidence, likely supporting share price.
Acquisition of Nanyue BioPharma strengthens competitive position; long-term positive for company growth.
Efficient use of funds expected to reinforce core competitiveness and profitability.
Final implementation depends on shareholder approval; investors should monitor progress.

4. Summary

Shanghai RAAS’s 2025 profit distribution proposal demonstrates steady operations, clear dividend policy, strong repurchase, completed acquisition of Nanyue BioPharma, and rational fund utilization. Overall, it is positive for investors and shareholders’ long-term interests and deserves close attention.

Disclaimer

This article is for informational interpretation only and does not constitute investment advice. The profit distribution proposal is subject to final approval; investors should pay attention to subsequent company announcements and make prudent decisions. The market involves risks; invest cautiously.